A prospective proof-of-concept study by Nicolau et al 19 found that liraglutide treatment for three months resulted in a decrease in BMI (from 39.3 to 35.6 kg/m 2 ), waist circumference (from 121.3 to 110.6 cm), mean Hurley stage (from 2.6 to 1.1), DLQI (from 12.3 to 9.7), Beck Depression Inventory (BDI) (from 22 to 16.7), and visual analog scale (VAS) for pain (from 5.6 to 3.2), as well as a decrease in inflammatory markers such as CRP (from 4.5 to 3 mg/dL), homocysteine (from 16.2 to 13.3 mol/L), plasma morning cortisol (from 15.9 to 12.6 g/dL), and insulin (from 18.9 to 15.7 U/mL)
Reproductive planning decisions must always involve your obstetrician
There is no established pharmacological mechanism by which GLP-1 receptor activation would directly cause muscle pain or damage
Obesity is a major risk factor for T2D and for neuropathy
If your retatrutide was left out for less than 24 hours, it is generally still usable